ArticleAnais brasileiros de dermatologia
The Brazilian Portuguese version of the psoriasis epidemiology screening tool (PEST-bp) is reliable and accurate: a cross-sectional study from southern Brazil.
Article in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on "The Brazilian Portuguese version of the psoriasis epidemiology screening tool (PEST-bp) is reliable and accurate: a cross-sectional study from southern Brazil" - Reply.Anais brasileiros de dermatologiaArticle
- Comment on "The Brazilian Portuguese version of the psoriasis epidemiology screening tool (PEST-bp) is reliable and accurate: a cross-sectional study from southern Brazil".Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriatic arthritis (PsA) remains diagnostically challenging in clinical practice. The Psoriasis Epidemiology Screening Tool - Brazilian Portuguese version (PEST-BP) offers a potential solution for simplified case identification.
objectiveTo evaluate the diagnostic accuracy of PEST-BP in detecting PsA among patients with psoriasis in a novel Southern Brazilian population.
methodsIn this cross-sectional study, psoriasis patients from a dermatology clinic underwent dual assessment: PEST-BP screening and gold-standard rheumatologic evaluation using CASPAR criteria for PsA diagnosis. Statistical analyses included sensitivity, specificity, and ROC curve determination.
resultsAmong 100 patients, 21 (21%) met the CASPAR criteria for PsA. A PEST-BP score ≥ 3 showed the best diagnostic performance with 81% sensitivity, 79.7% specificity, and 80% overall accuracy (AUC = 0.845, p < 0.001). Patients with PsA had a significantly higher prevalence of dactylitis (38.1% vs. 11.4%; p = 0.004), nail psoriasis (66.7% vs. 35.4%; p = 0.01), and Psoriasis Area and Severity Index (PASI) ≥ 10 (42.9% vs. 19%; p = 0.023). In multivariate analysis, a PEST-BP score ≥ 3 (OR = 32.43; p < 0.001) and PASI ≥ 10 (OR = 9.26; p = 0.007) were independently associated with PsA. STUDY LIMITATIONS: Single-center design in a tertiary care hospital and small sample size may overrepresent patients with severe disease.
conclusionThe PEST-BP is a reliable and accurate tool for PsA screening in Brazilian dermatology settings. Its simplicity and strong diagnostic performance support its integration into routine clinical practice for early PsA detection.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.